Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NOV-205 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single | EXPERIMENTAL | single-arm study |
| Name | Type | Description |
|---|---|---|
| NOV-205 | DRUG | There will be 4 treatment Groups with 10 patients in each group: * Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days * Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days * Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days * Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days |
Inclusion Criteria: * A serum HCV RNA level of \>100,000 IU/ml using a quantitative, branched-chain-DNA (bDNA)-based assay (lower limit of quantitation = \~650 IU/ml) or other equally sensitive quantitative methods. * Infection with genotype 1 HCV * Documented failure to respond to treatment (defin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
NOV-205 is an investigational small molecule being developed for the treatment of Hepatitis C. It is intended for patients who have failed standard therapy. The drug is currently in clinical development and has not been approved by regulatory authorities.
NOV-205 is being developed by Cellectar Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLRB. The company is conducting clinical trials to evaluate the safety and efficacy of NOV-205 in patients with Hepatitis C.
NOV-205 is in Phase 2 clinical development. It has completed a Phase 1 study and a Phase 2 study, both in patients with Hepatitis C who failed standard therapy. The drug remains investigational and is not yet approved for commercial use.
NOV-205 has been studied in two completed clinical trials. NCT00372983 was a Phase 1 safety and pharmacokinetics study in 30 patients with chronic Hepatitis C who failed standard therapy. NCT01058512 was a Phase 2 trial in 22 Hepatitis C patients in the United States who failed standard therapy.
NOV-205 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a small molecule being evaluated specifically for Hepatitis C, distinct from other antiviral agents in the same therapeutic area.